http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104262468-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-765 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 |
| filingDate | 2014-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-104262468-B |
| titleOfInvention | Glucose transporter inhibiting polypeptide as well as preparation method and application thereof |
| abstract | The invention provides a glucose transporter inhibiting polypeptide as well as a preparation method and application thereof, relating to the field of medicines. The invention in particular relates to a polypeptide 1 compound which can be used for treating diabetes mellitus. The sequence of the polypeptide 1 is MEPSSKKLTGIFAGGSVGGMIGS. The preparation method of the polypeptide 1 is characterized in that the polypeptide 1 is prepared by adopting the Fmoc protected solid phase synthesis technology; the polypeptide 1 can be covalently linked with an adjuvant which is bovine serum albumin, human serum albumin or polyethylene glycol. The invention provides the application of the polypeptide 1 to treatment of diabetes mellitus and complications of diabetes mellitus, wherein the complications of diabetes mellitus include diabetic nephropathy, diabetic hypertension, diabetic eye diseases and diabetic neuropathy; the polypeptide 1 can be used for treating diabetes mellitus and complications of diabetes mellitus through various modes of administration, including hypodermic or intramuscular injection, intravenous injection or intravenous drip, administration of oral medicines, such as pills, capsules, and the like, nasal spray, and the like. The glucose transporter inhibiting polypeptide 1 provided by the invention can inhibit glucose transporters in a targeted manner, thus achieving the effect of preventing or treating diabetes mellitus. |
| priorityDate | 2014-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 113.